Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1995 1
1996 2
1998 5
1999 1
2000 2
2002 3
2003 2
2004 3
2005 1
2006 1
2007 6
2008 6
2009 7
2010 2
2011 11
2012 11
2013 7
2014 8
2015 13
2016 10
2017 5
2018 5
2019 2
2020 6
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 23668425

108 results
Results by year
Filters applied: . Clear all
Page 1
Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes?
Nagendran J, Oudit GY, Bakal JA, Light PE, Dyck JR, McAlister FA. Nagendran J, et al. Diabetes Obes Metab. 2013 Nov;15(11):1022-8. doi: 10.1111/dom.12126. Epub 2013 Jun 3. Diabetes Obes Metab. 2013. PMID: 23668425
Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
Abdelmoneim AS, Eurich DT, Gamble JM, Johnson JA, Seubert JM, Qiu W, Simpson SH. Abdelmoneim AS, et al. Diabetes Obes Metab. 2014 Jan;16(1):22-9. doi: 10.1111/dom.12173. Epub 2013 Jul 19. Diabetes Obes Metab. 2014. PMID: 23802997
Neither diabetes nor glucose-lowering drugs are associated with mortality after noncardiac surgery in patients with coronary artery disease or heart failure.
Hanninen M, McAlister FA, Bakal JA, van Diepen S, Ezekowitz JA. Hanninen M, et al. Can J Cardiol. 2013 Apr;29(4):423-8. doi: 10.1016/j.cjca.2012.07.004. Epub 2012 Sep 15. Can J Cardiol. 2013. PMID: 22985785
Controversies in management of diabetes in patients with coronary heart disease.
Abdella NA. Abdella NA. Med Princ Pract. 2002;11 Suppl 2:69-74. doi: 10.1159/000066410. Med Princ Pract. 2002. PMID: 12444313 Free article. Review.
Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS).
Leibovitz E, Gottlieb S, Goldenberg I, Gevrielov-Yusim N, Matetzky S, Gavish D. Leibovitz E, et al. Cardiovasc Diabetol. 2013 Mar 28;12:53. doi: 10.1186/1475-2840-12-53. Cardiovasc Diabetol. 2013. PMID: 23537430 Free PMC article.
Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
Fasching P. Fasching P. Diabetologia. 1998 Jun;41(6):743-4. doi: 10.1007/s001250050981. Diabetologia. 1998. PMID: 9662063 No abstract available.
[Increased cardiovascular risk in patients with type 2 diabetes treated with sulfonylurea?].
Asvold BO, Jonsbu M, Grill V. Asvold BO, et al. Tidsskr Nor Laegeforen. 2000 Sep 10;120(21):2560-4. Tidsskr Nor Laegeforen. 2000. PMID: 11070997 Review. Norwegian.
Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study.
Eurich DT, Weir DL, Simpson SH, Senthilselvan A, McAlister FA. Eurich DT, et al. Diabet Med. 2016 May;33(5):621-30. doi: 10.1111/dme.12867. Epub 2015 Aug 25. Diabet Med. 2016. PMID: 26206341
The clinical effects of levosimendan are not attenuated by sulfonylureas.
Kivikko M, Nieminen MS, Pollesello P, Pohjanjousi P, Colucci WS, Teerlink JR, Mebazaa A. Kivikko M, et al. Scand Cardiovasc J. 2012 Dec;46(6):330-8. doi: 10.3109/14017431.2012.725206. Epub 2012 Sep 25. Scand Cardiovasc J. 2012. PMID: 22928945
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS. Pantalone KM, et al. Acta Diabetol. 2009 Jun;46(2):145-54. doi: 10.1007/s00592-008-0090-3. Epub 2009 Feb 5. Acta Diabetol. 2009. PMID: 19194648
108 results
Jump to page
Feedback